Targetable Gene Rearrangements in Advanced Lung Cancer: Optimized Testing and Management

home / insights / targetable-gene-rearrangements-in-advanced-lung-cancer-optimized-testing-and-management

This OncLive Insights features 3 experts who share their thoughts on how the treatment landscape of advanced NSCLC is evolving through use of comprehensive genetic sequencing to identify actionable biomarkers. They summarize how novel therapeutics which target driver alterations in ALK, ROS, RET, or NTRK can be leveraged to personalize and optimize management of advanced NSCLC, ultimately improving survival outcomes.